VivoSeq
Other

Visual Acuity

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Visual Acuity is an early-stage landscape with 0 programs across 1 company. The most active players are Johnson & Johnson Vision Care, Inc..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

J

Johnson & Johnson Vision Care, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

8

clinical trials

Completed6 · 75%
Active, not recruiting1 · 13%
Withdrawn1 · 13%

Clinical Trials

Trial Activity

8 trials

Mean Visual Acuity Changes Following Five Injections of Aflibercept
Active, not recruiting·MMcMaster University·N/A·NCT02645266·48 enrolled
Clinical Investigation of Visual Acuity in Contact Lens Wearers After Instillation of Investigational Lubricating Eye Drops
Completed·JJohnson & Johnson Vision Care, Inc.·Phase 2·NCT05814367·46 enrolled
Clinical Investigation of Visual Acuity in Contact Lens Wearers After Instillation of a Lipid- Based Lubricating Eye Drop
Completed·JJohnson & Johnson Vision Care, Inc.·Phase 1·NCT06131476·32 enrolled
Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity
Completed·UUniversity of California, San Diego·N/A·NCT03931317·70 enrolled
Evaluation of Approved Contact Lenses
Completed·JJohnson & Johnson Vision Care, Inc.·Preclinical·NCT07174596·85 enrolled
Clinical Evaluation of Two Cosmetic Contact Lenses
Completed·JJohnson & Johnson Vision Care, Inc.·Preclinical·NCT06864858·53 enrolled
Pilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses
Completed·JJohnson & Johnson Vision Care, Inc.·Preclinical·NCT07076160·74 enrolled
Evaluating the Link Between Active Neovascularization Found on OCT and Eye Fixation Quality Measured With Microperimetry in ARMD Patients Treated With antiVEGF
Withdrawn·UUniversity Hospital, Limoges·N/A·NCT03435926

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)